EXPLORE THE EFFICACY AND SAFETY OF ONCE-DAILY ORAL RIVAROXABAN FOR THE PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH NON- VALVULAR ATRIAL FIBRILLATION SCHEDULED FOR CARDIOVERSION
Abstract
Cappato R., Ezekowitz M.D., Klein A.L., et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation // Eur. heart J. – 2014. Sep. 2. [Epub ahead of print].
Review
For citations:
EXPLORE THE EFFICACY AND SAFETY OF ONCE-DAILY ORAL RIVAROXABAN FOR THE PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH NON- VALVULAR ATRIAL FIBRILLATION SCHEDULED FOR CARDIOVERSION. Russian Sklifosovsky Journal "Emergency Medical Care". 2014;(4):66-67. (In Russ.)
Views:
530
Email this article 